Since HER2 and EGFR receptors activate the same signaling cascades, the finding of mutual exclusive amplification indicates that alteration of either gene is sufficient for gastric cancer cells, and that different subclones of the tumor may have developed HER2 and EGFR amplification independently from each other. This evidence concerns the gene ERBB2 and gastric cancer.